<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03431467</url>
  </required_header>
  <id_info>
    <org_study_id>828198</org_study_id>
    <nct_id>NCT03431467</nct_id>
  </id_info>
  <brief_title>Impella CP With VA ECMO for Cardiogenic Shock</brief_title>
  <acronym>REVERSE</acronym>
  <official_title>A Prospective Randomised Trial of Early LV Venting Using Impella CP for Recovery in Patients With Cardiogenic Shock Managed With VA ECMO</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Veno-arterial extra-corporeal membrane oxygenation (VA-ECMO) is indicated as a haemodynamic&#xD;
      rescue strategy in decompensated acute or chronic heart failure presenting as cardiogenic&#xD;
      shock. It has been used across aeitologies including post-myocardial infarction, dilated&#xD;
      cardiomyopathy, acute myocarditis and in post-cardiotomy shock. VA ECMO has a number of&#xD;
      effects on the circulation including improved end-organ perfusion and possibly improved&#xD;
      coronary perfusion, and is a bridge to further therapies including permanent advanced&#xD;
      mechanical circulatory support, cardiac transplantation and to cardiac recovery.&#xD;
&#xD;
      Left ventricular assist devices (LVADs) provide long-term mechanical circulatory support and&#xD;
      also profoundly mechanically unload the left ventricle. Multiple clinical studies have&#xD;
      documented cardiac recovery using LVAD therapy, with a rate between 10-60% in selected&#xD;
      populations. A large body of basic science has documented the pivotal role of mechanical load&#xD;
      in determining ventricular contractile performance across species. Therefore both clinical&#xD;
      data and basic laboratory studies support the notion that profound ventricular unloading may&#xD;
      result in improved cardiac performance through a variety of mechanisms ranging from triggered&#xD;
      de novo cardiomyocyte proliferation, subcellular calcium handling reverse remodeling, changes&#xD;
      to the extracellular matrix of the heart, reverse remodeling of the neurohormal milleu,&#xD;
      amongst many others.&#xD;
&#xD;
      One of the major deficiencies of peripheral VA-ECMO is its lack of left ventricular&#xD;
      unloading, with associated pulmonary congestion, which can derail clinical improvement and&#xD;
      hamper cardiac recovery. Indeed, percutaneous VA-ECMO increases LV afterload due to the&#xD;
      retrograde blood flow, and because of the lack of venting, there may be progressive LV&#xD;
      distension. These conditions can result in a congested, pressure-overloaded ventricle, even&#xD;
      in the absence of echocardiographic ventricular distension. This may be ameliorated with the&#xD;
      addition of ventricular mechanical unloading using percutaneous therapies including the&#xD;
      percutaneous left ventricular device, Impella CP.&#xD;
&#xD;
      On the platform of VA-ECMO, the addition of an Impella device to reduce ventricular loading&#xD;
      results in improved survival and recovery of ventricular performance in the setting of&#xD;
      cardiogenic shock. In a number of small studies, the use of additional means to unload the&#xD;
      ventricle, principally Impella, results in cardiac recovery and less ventricular distension.&#xD;
      In chronic heart failure, direct ventricular unloading is critical to cardiac recovery.&#xD;
&#xD;
      The objective of this randomized study is to determine whether the addition of early direct&#xD;
      ventricular unloading using Impella CP leads to higher rates of cardiac recovery, defined as&#xD;
      survival free from mechanical circulatory support, heart transplantation or inotropic support&#xD;
      at thirty days. This study will also examine the clinical, biochemical, echocardiographic and&#xD;
      radiologic effects of VA ECMO with and without the addition of Impella CP to directly vent&#xD;
      the left ventricle to address adjunct important questions such as the effects on pulmonary&#xD;
      congestion.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 19, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised controlled trial at three U Penn Sites</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>All data will be masked as far as possible. For example, Echo data will be masked</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Recovery from cardiogenic shock.</measure>
    <time_frame>At thirty days.</time_frame>
    <description>Proportion of subjects treated with this standardized ECMO protocol with either (i) no additional therapy or (ii) Impella CP for LV mechanical unloading who experience myocardial recovery defined as: survival free from mechanical circulatory support, heart transplantation or inotropic support.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Survival to hospital discharge.</measure>
    <time_frame>At discharge from hospital, an average of 60 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">96</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>VA-ECMO alone per standard clinical protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VA-ECMO with early institution of Impella CP LV venting</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Impella-CP LV Vent</intervention_name>
    <description>Patients randomised to the experimental arm will have an Impella-CP implanted in addition to VA-ECMO within a maximum of 10 hours of institution of VA-ECMO</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Cardiogenic shock: Including refractory to conventional therapy, including systolic&#xD;
             blood pressure &lt; 90mm Hg, Cardiac Index &lt; 1.8 or a cardiac index &lt; 2.0 on moderate to&#xD;
             high doses of inotropes and vasopressors for greater than 30 mins, or systemic signs&#xD;
             of tissue hypoxia.&#xD;
&#xD;
          -  Post-acute myocardial infarction cardiogenic shock: excluding mechanical complications&#xD;
             requiring surgical intervention after extracorpeal membrane oxygenator (ECMO) such as&#xD;
             post-ischaemic ventricular septal defect (VSD).&#xD;
&#xD;
          -  Drug overdose-induced cardiogenic shock.&#xD;
&#xD;
          -  Early graft failure: post orthotropic heart transplantation cardiogenic shock,&#xD;
             excluding immediate intra-operative failure.&#xD;
&#xD;
          -  Acute on chronic cardiomyopathy with progressive shock and decompensation unresponsive&#xD;
             to medical therapies.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Recent Significant Pulmonary Embolus&#xD;
&#xD;
          -  Moderate to severe aortic valve insufficiency (AI)&#xD;
&#xD;
          -  Ongoing significant sepsis&#xD;
&#xD;
          -  Severe pulmonary hypertension &amp; shock&#xD;
&#xD;
          -  Hypothermia&#xD;
&#xD;
          -  Post-cardiotomy cardiogenic shock&#xD;
&#xD;
          -  Continuous cardiopulmonary resuscitation (CPR) &gt;20-30 minutes, except if neurological&#xD;
             status is satisfactory&#xD;
&#xD;
          -  Transfer from outside hospital on VA ECMO or with history of CPR&#xD;
&#xD;
          -  Listed for cardiopulmonary transplantation or being evaluated for cardiopulmonary&#xD;
             transplantation or permanent mechanical circulatory support&#xD;
&#xD;
          -  Known or suspected chronic heart failure with echocardiogram documenting left&#xD;
             ventricular diastolic diameter &gt;6.5cm&#xD;
&#xD;
          -  Known or suspected chronic heart failure with echocardiogram documenting left&#xD;
             ventricular ejection fraction &lt; 25%&#xD;
&#xD;
          -  Mechanical aortic valve replacement&#xD;
&#xD;
          -  Presence of left ventricular thrombus&#xD;
&#xD;
          -  Pre-existing Impella 2.5, CP, 3.5 or 5.0&#xD;
&#xD;
          -  Cardiogenic shock due to primary respiratory failure&#xD;
&#xD;
          -  Mechanical complications requiring surgical intervention after ECMO such as&#xD;
             post-ischaemic VSD.&#xD;
&#xD;
          -  Severe liver failure&#xD;
&#xD;
          -  Active malignancy&#xD;
&#xD;
          -  Acute aortic dissection&#xD;
&#xD;
          -  Intracranial hemorrhage&#xD;
&#xD;
          -  Neurological injury including recent cerebrovascular accident or suspected severe&#xD;
             neurologic injury&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Bermudez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Ibrahim, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Michael Ibrahim, MD PhD</last_name>
    <phone>2677605502</phone>
    <email>michael.ibrahim@uphs.upenn.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital of The University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Ibrahim, MD PhD</last_name>
      <email>michael.ibrahim@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michael Ibrahim</last_name>
      <email>michael.ibrahim@uphs.upenn.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 21, 2018</study_first_submitted>
  <study_first_submitted_qc>February 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2018</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Michael Ibrahim</investigator_full_name>
    <investigator_title>Co-Principal Investogator</investigator_title>
  </responsible_party>
  <keyword>ECMO</keyword>
  <keyword>Heart Failure</keyword>
  <keyword>RCT</keyword>
  <keyword>Mechanical unloading</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Deidentiifed data will be used within the research team</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03431467/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 20, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03431467/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

